J
Jianping Weng
Researcher at University of Science and Technology of China
Publications - 347
Citations - 13912
Jianping Weng is an academic researcher from University of Science and Technology of China. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 46, co-authored 274 publications receiving 10666 citations. Previous affiliations of Jianping Weng include Malmö University & Chinese Academy of Sciences.
Papers
More filters
Journal ArticleDOI
Prevalence of Diabetes among Men and Women in China
Wenying Yang,Juming Lu,Jianping Weng,Weiping Jia,Linong Ji,Jianzhong Xiao,Zhongyan Shan,Jie Liu,Haoming Tian,Qiuhe Ji,Dalong Zhu,Jiapu Ge,Lixiang Lin,Li Chen,Xiaohui Guo,Zhigang Zhao,Qiang Li,Zhiguang Zhou,Guangliang Shan,Jiang He +19 more
TL;DR: The prevalence of diabetes among Chinese adults and prediabetes, which included both previously diagnosed diabetes and previously undiagnosed diabetes, was estimated to be 9.7% and 15.5% respectively, respectively, from a national study conducted from June 2007 through May 2008.
Journal ArticleDOI
Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial
Jianping Weng,Yanbing Li,Wen Xu,Lixin Shi,Qiao Zhang,Dalong Zhu,Yun Hu,Zhiguang Zhou,Xiang Yan,Haoming Tian,Xingwu Ran,Zuojie Luo,Jing Xian,Li Yan,Fangping Li,Longyi Zeng,Yanming Chen,Liyong Yang,Sunjie Yan,Juan Liu,Ming Li,Zuzhi Fu,Hua Cheng +22 more
TL;DR: Early intensive insulin therapy in patients with newly diagnosed type 2 diabetes has favourable outcomes on recovery and maintenance of beta-cell function and protracted glycaemic remission compared with treatment with oral hypoglycaemic agents.
Journal ArticleDOI
The many faces of diabetes: a disease with increasing heterogeneity
Tiinamaija Tuomi,Nicola Santoro,Sonia Caprio,Mengyin Cai,Jianping Weng,Leif Groop,Leif Groop +6 more
TL;DR: Diabetes is a much more heterogeneous disease than the present subdivision into types 1 and 2 assumes; type 1 and type 2 diabetes probably represent extremes on a range of diabetic disorders.
Journal ArticleDOI
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Roden,Jianping Weng,Jens Eilbracht,Bruno Delafont,G. Kim,Hans-Juergen Woerle,Uli C. Broedl +6 more
TL;DR: Empagliflozin provides a tolerable and efficacious strategy to reduce HbA1c in patients with type 2 diabetes who had not previously received drug treatment.
Journal ArticleDOI
Biochemical characterization of SARS-CoV-2 nucleocapsid protein.
Weihong Zeng,Guangfeng Liu,Huan Ma,Dan Zhao,Yunru Yang,Muziying Liu,Ahmed Mohammed,Changcheng Zhao,Yun Yang,Jiajia Xie,Chengchao Ding,Xiaoling Ma,Jianping Weng,Yong Gao,Hongliang He,Tengchuan Jin,Tengchuan Jin +16 more
TL;DR: Immunoblot assays confirmed the presence of IgA, IgM and IgG antibodies against N antigen in COVID-19 infection patients' sera, proving the importance of this antigen in host immunity and diagnostics.